Stock Track | Harrow Health (HROW) Soars 5.03% as Multiple Analysts Raise Price Targets

Stock Track11-12

Harrow Health Inc (HROW) shares surged 5.03% in pre-market trading on Wednesday, following a series of positive analyst reports that raised price targets for the company's stock. The surge comes as investors react to the bullish sentiment from Wall Street analysts.

H.C. Wainwright led the charge by increasing its price target on Harrow from $64 to $69, while maintaining a Buy rating. The firm cited a "robust" report from the company, although specific details were not provided. Similarly, Ladenburg analyst Jeffrey Cohen raised his price target to $66 from $64, also keeping a Buy rating on the shares. Lake Street reaffirmed its Buy rating on Harrow Health, further bolstering investor confidence.

These upgrades suggest that analysts are increasingly optimistic about Harrow Health's future prospects. The company, which specializes in the development, production, and sale of innovative ophthalmic products, appears to be impressing Wall Street with its performance and outlook. As investors digest these positive assessments, the stock's pre-market rally indicates growing enthusiasm for Harrow Health's potential in the healthcare sector.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186612675?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 22:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186612675","market":"us","top_or_hot":-1,"title":"Stock Track | Harrow Health (HROW) Soars 5.03% as Multiple Analysts Raise Price Targets","media":"Stock Track","content":"<p>Harrow Health Inc (HROW) shares surged 5.03% in pre-market trading on Wednesday, following a series of positive analyst reports that raised price targets for the company's stock. The surge comes as investors react to the bullish sentiment from Wall Street analysts.</p>\n\n<p>H.C. Wainwright led the charge by increasing its price target on Harrow from $64 to $69, while maintaining a Buy rating. The firm cited a \"robust\" report from the company, although specific details were not provided. Similarly, Ladenburg analyst Jeffrey Cohen raised his price target to $66 from $64, also keeping a Buy rating on the shares. Lake Street reaffirmed its Buy rating on Harrow Health, further bolstering investor confidence.</p>\n\n<p>These upgrades suggest that analysts are increasingly optimistic about Harrow Health's future prospects. The company, which specializes in the development, production, and sale of innovative ophthalmic products, appears to be impressing Wall Street with its performance and outlook. As investors digest these positive assessments, the stock's pre-market rally indicates growing enthusiasm for Harrow Health's potential in the healthcare sector.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Harrow Health (HROW) Soars 5.03% as Multiple Analysts Raise Price Targets</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Harrow Health (HROW) Soars 5.03% as Multiple Analysts Raise Price Targets\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-12 22:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Harrow Health Inc (HROW) shares surged 5.03% in pre-market trading on Wednesday, following a series of positive analyst reports that raised price targets for the company's stock. The surge comes as investors react to the bullish sentiment from Wall Street analysts.</p>\n\n<p>H.C. Wainwright led the charge by increasing its price target on Harrow from $64 to $69, while maintaining a Buy rating. The firm cited a \"robust\" report from the company, although specific details were not provided. Similarly, Ladenburg analyst Jeffrey Cohen raised his price target to $66 from $64, also keeping a Buy rating on the shares. Lake Street reaffirmed its Buy rating on Harrow Health, further bolstering investor confidence.</p>\n\n<p>These upgrades suggest that analysts are increasingly optimistic about Harrow Health's future prospects. The company, which specializes in the development, production, and sale of innovative ophthalmic products, appears to be impressing Wall Street with its performance and outlook. As investors digest these positive assessments, the stock's pre-market rally indicates growing enthusiasm for Harrow Health's potential in the healthcare sector.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HROW","symbol_name":"Harrow Health Inc","start_time":0,"source_url":"","article_id":"1186612675","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186612675","pubTimestamp":1762958662,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Harrow Health Inc (HROW) shares surged 5.03% in pre-market trading on Wednesday, following a series of positive analyst reports that raised price targets for the company's stock. The surge comes as...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HROW":"Harrow Health Inc"},"translate_title":"个股追踪|多位分析师上调目标价，哈罗健康(HROW)飙升5.03%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HROW":1},"content_text":"Harrow Health Inc (HROW) shares surged 5.03% in pre-market trading on Wednesday, following a series of positive analyst reports that raised price targets for the company's stock. The surge comes as investors react to the bullish sentiment from Wall Street analysts.\nH.C. Wainwright led the charge by increasing its price target on Harrow from $64 to $69, while maintaining a Buy rating. The firm cited a \"robust\" report from the company, although specific details were not provided. Similarly, Ladenburg analyst Jeffrey Cohen raised his price target to $66 from $64, also keeping a Buy rating on the shares. Lake Street reaffirmed its Buy rating on Harrow Health, further bolstering investor confidence.\nThese upgrades suggest that analysts are increasingly optimistic about Harrow Health's future prospects. The company, which specializes in the development, production, and sale of innovative ophthalmic products, appears to be impressing Wall Street with its performance and outlook. As investors digest these positive assessments, the stock's pre-market rally indicates growing enthusiasm for Harrow Health's potential in the healthcare sector.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186612675","isCrawlerRequest":true}